Is Protagonist Therapeutics Inc (PTGX) overvalued? · rev $269.8M
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
This page asks whether Protagonist Therapeutics Inc (PTGX) looks expensive on cached numbers — not a short thesis.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
PTGX currently screens at market cap $7.25B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PTGX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PTGX stock page for the full model, not this heading.
Not investment advice.